Royal Bank of Canada Reiterates Outperform Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $16.00 target price on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 395.36% from the company’s previous close.

A number of other equities analysts have also weighed in on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target for the company. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Finally, UBS Group started coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Stock Performance

NYSE:CATX traded down $0.17 on Tuesday, hitting $3.23. 396,870 shares of the stock were exchanged, compared to its average volume of 1,013,371. The stock has a fifty day moving average of $4.98 and a 200-day moving average of $10.20. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million during the quarter. As a group, research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Activity at Perspective Therapeutics

In other news, Director Heidi Henson bought 25,975 shares of the stock in a transaction on Wednesday, December 4th. The stock was acquired at an average price of $3.85 per share, with a total value of $100,003.75. Following the acquisition, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Johan M. Spoor acquired 14,500 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the purchase, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 67,570 shares of company stock valued at $256,789 over the last ninety days. 3.52% of the stock is owned by corporate insiders.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the last quarter. State Street Corp lifted its holdings in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Nicholson Wealth Management Group LLC purchased a new stake in Perspective Therapeutics during the third quarter worth about $21,390,000. Finally, Geode Capital Management LLC grew its position in shares of Perspective Therapeutics by 12.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after acquiring an additional 129,654 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.